Procept says NICE gave ‘standard arrangements’ recommendation on Aquablation

PROCEPT BioRobotics announces that the National Institute for Health and Care Excellence, NICE, has bestowed its strongest endorsement, the “standard arrangements” recommendation, on Aquablation therapy for the treatment of benign prostatic hyperplasia, BPH. NICE plays a pivotal role in providing guidance to enhance health and social care in the United Kingdom. For a procedure to secure such a recommendation, it must demonstrate both short-term and long-term safety and efficacy. NICE’s endorsement underscores that the robotically assisted Aquablation therapy meets these rigorous standards. “After an extensive multi-year evaluation, we’re elated to share that Aquablation therapy has received the top-tier recommendation from NICE,” said Sham Shiblaq, Executive Vice President and Chief Commercial Officer of PROCEPT BioRobotics. “Although NICE’s purview is the UK, its clinical endorsements have significant international influence. This bolsters our conviction that Aquablation therapy is on course to be the global standard of care for BPH.”